| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 3.38 | 4.6% | 111.3% |
| Total Income | 3.38 | 4.6% | 111.3% |
| Expenditure | 32.28 | 24.5% | 43.1% |
| PBT | — | ||
| Net Profit | -24.14 | 31.7% | 33.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.44 | 15.8% | 98.0% |
Aktis Oncology Reports Q2 2026 Financial Results and Business Highlights
14 Aug 2026 · 14 Aug, 1:40 am
Summary
Aktis Oncology reported its financial results and business highlights for the second quarter ended June 30, 2026. Collaboration revenue increased to $3.4 million, driven by the research collaboration with Eli Lilly and Company. The company experienced an increase in net loss to $24.1 million, primarily due to higher operating expenses in research and development and general and administrative functions. However, the company's cash position strengthened significantly to $517.3 million, providing runway into 2029.
Key Highlights
- 1
Aktis Oncology reported financial results and business highlights for the second quarter ended June 30, 2026.
- 2
Collaboration revenue was $3.4 million for the quarter ended June 30, 2026, an increase of $1.8 million compared to the comparable prior-year period.
- 3
Research and development expenses were $25.3 million for the quarter ended June 30, 2026, an increase of $6.7 million compared to the comparable prior-year period.
- 4
General and administrative expenses were $7.0 million for the quarter ended June 30, 2026, an increase of $3.1 million compared to the comparable prior-year period.
- 5
Net loss was $24.1 million for the quarter ended June 30, 2026, an increase of $6.0 million compared to the comparable prior-year period.
- 6
Cash, cash equivalents, and marketable securities were $517.3 million as of June 30, 2026, expected to fund the Company’s operating plan into 2029.
Management Comments
Matthew Roden
This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to support our clinical pipeline. Our AKY-2519 clinical imaging and dosimetry data presented at ASCO generated significant enthusiasm among clinical investigators, helping to advance enrollment in the ongoing Phase 1b trials of AKY-1189 and AKY-2519, and setting the stage for a data-rich 2027. In the second half of 2026, we expect to initiate the Phase 1b trial with AKY-2519 in B7-H3 expressing solid tumors, representing our third Phase 1b trial. We also expect to continue operationalizing our internal GMP facility as part of our comprehensive strategy to enable our own clinical supply for our pipeline. We believe that the breadth of our pipeline, together with our proprietary miniprotein radioconjugate platform and reliable end-to-end supply chain, position us for leadership in targeted radiopharmaceuticals.
Informational and educational content only. Not investment advice.